The Immunological Organ Environment Dictates the Molecular and Cellular Pathways of Cytotoxic Antibody Activity

Cell Reports

Volumn 29, Issue 10, 2019, Pages 3033-3046.e4

  Gordan, Sina ^a   Albert, Heike ^a   Danzer, Heike ^a   Lux, Anja ^a   Biburger, Markus ^a   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

antibody dependent cellular cytotoxicity; complement; cytotoxic antibody; Fc receptor; immunoglobulin G; macrophage; natural killer cell; phagocytosis

Indexed keywords

CYTOTOXIC ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; C57BL 6 MOUSE; CELL KILLING; COHORT ANALYSIS; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNE SYSTEM; LYMPHOCYTE DEPLETION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; TARGET CELL; THERAPY EFFECT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; C57BL MOUSE; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FEMALE; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, INBRED C57BL; RECEPTORS, IGG; SPLEEN;

EID: 85075679874     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2019.10.111     Document Type: Article

References (74)

1. Albanesi, M., Mancardi, D.A., Macdonald, L.E., Iannascoli, B., Zitvogel, L., Murphy, A.J., Daëron, M., Leusen, J.H., Bruhns, P., Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J. Immunol. 189 (2012), 5513–5517.
2. Albanesi, M., Mancardi, D.A., Jönsson, F., Iannascoli, B., Fiette, L., Di Santo, J.P., Lowell, C.A., Bruhns, P., Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122 (2013), 3160–3164.
3. Aloulou, M., Ben Mkaddem, S., Biarnes-Pelicot, M., Boussetta, T., Souchet, H., Rossato, E., Benhamou, M., Crestani, B., Zhu, Z., Blank, U., et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood 119 (2012), 3084–3096.
4. Arce Vargas, F., Furness, A.J.S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. Melanoma TRACERx Consortium Renal TRACERx Consortium, Lung TRACERx Consortium. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity 46 (2017), 577–586.
5. Arce Vargas, F., Furness, A.J.S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M.H., Ruef, N., Roddie, C., et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell 33 (2018), 649–663.e4.
6. Auffray, C., Sieweke, M.H., Geissmann, F., Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27 (2009), 669–692.
7. Barnes, N., Gavin, A.L., Tan, P.S., Mottram, P., Koentgen, F., Hogarth, P.M., FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16 (2002), 379–389.
8. Beers, S.A., Chan, C.H., James, S., French, R.R., Attfield, K.E., Brennan, C.M., Ahuja, A., Shlomchik, M.J., Cragg, M.S., Glennie, M.J., Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112 (2008), 4170–4177.
9. Beers, S.A., Cragg, M.S., Glennie, M.J., Complement: help or hindrance?. Blood 114 (2009), 5567–5568.
10. Beers, S.A., Chan, C.H., French, R.R., Cragg, M.S., Glennie, M.J., CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47 (2010), 107–114.
11. Beers, S.A., French, R.R., Chan, H.T., Lim, S.H., Jarrett, T.C., Vidal, R.M., Wijayaweera, S.S., Dixon, S.V., Kim, H., Cox, K.L., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115 (2010), 5191–5201.
12. Ben Mkaddem, S., Benhamou, M., Monteiro, R.C., Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools. Front. Immunol., 10, 2019, 811.
13. Bevaart, L., Jansen, M.J., van Vugt, M.J., Verbeek, J.S., van de Winkel, J.G., Leusen, J.H., The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66 (2006), 1261–1264.
14. Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., Nimmerjahn, F., Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35 (2011), 932–944.
15. Biburger, M., Lux, A., Nimmerjahn, F., How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv. Immunol. 124 (2014), 67–94.
16. Borsos, T., Rapp, H.J., Complement fixation on cell surfaces by 19S and 7S antibodies. Science 150 (1965), 505–506.
17. Bournazos, S., Ravetch, J.V., Fcγ receptor pathways during active and passive immunization. Immunol. Rev. 268 (2015), 88–103.
18. Braster, R., O'Toole, T., van Egmond, M., Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 65 (2014), 28–37.
19. Brühl, H., Cihak, J., Schneider, M.A., Plachý, J., Rupp, T., Wenzel, I., Shakarami, M., Milz, S., Ellwart, J.W., Stangassinger, M., et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol. 172 (2004), 890–898.
20. Bruhns, P., Samuelsson, A., Pollard, J.W., Ravetch, J.V., Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (2003), 573–581.
21. Buchan, S.L., Dou, L., Remer, M., Booth, S.G., Dunn, S.N., Lai, C., Semmrich, M., Teige, I., Martensson, L., Penfold, C.A., et al. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. Immunity 49 (2018), 958–970.e7.
22. Carroll, M.C., The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004), 981–986.
23. Castro-Dopico, T., Clatworthy, M.R., Fcγ Receptors in Solid Organ Transplantation. Curr. Transplant. Rep. 3 (2016), 284–293.
24. Chao, M.P., Weissman, I.L., Majeti, R., The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24 (2012), 225–232.
25. Chiossone, L., Dumas, P.Y., Vienne, M., Vivier, E., Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18 (2018), 671–688.
26. Cragg, M.S., Glennie, M.J., Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004), 2738–2743.
27. Dahal, L.N., Roghanian, A., Beers, S.A., Cragg, M.S., FcγR requirements leading to successful immunotherapy. Immunol. Rev. 268 (2015), 104–122.
28. DiLillo, D.J., Ravetch, J.V., Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell 161 (2015), 1035–1045.
29. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
30. Gholamin, S., Mitra, S.S., Feroze, A.H., Liu, J., Kahn, S.A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med., 9, 2017, eaaf2968.
31. Gong, Q., Ou, Q., Ye, S., Lee, W.P., Cornelius, J., Diehl, L., Lin, W.Y., Hu, Z., Lu, Y., Chen, Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174 (2005), 817–826.
32. Gordan, S., Biburger, M., Nimmerjahn, F., bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. Immunol. Rev. 268 (2015), 52–65.
33. Gordon, S., Taylor, P.R., Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5 (2005), 953–964.
34. Grandjean, C.L., Montalvao, F., Celli, S., Michonneau, D., Breart, B., Garcia, Z., Perro, M., Freytag, O., Gerdes, C.A., Bousso, P., Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies. Sci. Rep., 6, 2016, 34382.
35. Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T.L., Kubes, P., van Egmond, M., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124 (2014), 812–823.
36. Hamaguchi, Y., Uchida, J., Cain, D.W., Venturi, G.M., Poe, J.C., Haas, K.M., Tedder, T.F., The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174 (2005), 4389–4399.
37. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., Tedder, T.F., Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (2006), 743–753.
38. Hanna, R.N., Carlin, L.M., Hubbeling, H.G., Nackiewicz, D., Green, A.M., Punt, J.A., Geissmann, F., Hedrick, C.C., The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat. Immunol. 12 (2011), 778–785.
39. Hazenbos, W.L., Gessner, J.E., Hofhuis, F.M., Kuipers, H., Meyer, D., Heijnen, I.A., Schmidt, R.E., Sandor, M., Capel, P.J., Daëron, M., et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5 (1996), 181–188.
40. Hogarth, P.M., Pietersz, G.A., Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11 (2012), 311–331.
41. Ji, H., Ohmura, K., Mahmood, U., Lee, D.M., Hofhuis, F.M., Boackle, S.A., Takahashi, K., Holers, V.M., Walport, M., Gerard, C., et al. Arthritis critically dependent on innate immune system players. Immunity 16 (2002), 157–168.
42. Kao, D., Danzer, H., Collin, M., Groß, A., Eichler, J., Stambuk, J., Lauc, G., Lux, A., Nimmerjahn, F., A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep. 13 (2015), 2376–2385.
43. Kimura, S., Tada, N., Nakayama, E., Liu, Y., Hämmerling, U., A new mouse cell-surface antigen (Ly-m20) controlled by a gene linked to Mls locus and defined by monoclonal antibodies. Immunogenetics 14 (1981), 3–14.
44. Kolev, M., Le Friec, G., Kemper, C., Complement--tapping into new sites and effector systems. Nat. Rev. Immunol. 14 (2014), 811–820.
45. Koo, G.C., Peppard, J.R., Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 3 (1984), 301–303.
46. Kurihara, T., Warr, G., Loy, J., Bravo, R., Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186 (1997), 1757–1762.
47. Lehmann, B., Biburger, M., Brückner, C., Ipsen-Escobedo, A., Gordan, S., Lehmann, C., Voehringer, D., Winkler, T., Schaft, N., Dudziak, D., et al. Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci. Immunol., 2, 2017, eaah6413.
48. López-Botet, M., Vilches, C., Redondo-Pachón, D., Muntasell, A., Pupuleku, A., Yélamos, J., Pascual, J., Crespo, M., Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. Front. Immunol., 8, 2017, 166.
49. Lux, A., Seeling, M., Baerenwaldt, A., Lehmann, B., Schwab, I., Repp, R., Meidenbauer, N., Mackensen, A., Hartmann, A., Heidkamp, G., et al. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 7 (2014), 236–248.
50. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., Allavena, P., Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14 (2017), 399–416.
51. Matlung, H.L., Babes, L., Zhao, X.W., van Houdt, M., Treffers, L.W., van Rees, D.J., Franke, K., Schornagel, K., Verkuijlen, P., Janssen, H., et al. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Rep. 23 (2018), 3946–3959.e6.
52. Mihai, S., Nimmerjahn, F., The role of Fc receptors and complement in autoimmunity. Autoimmun. Rev. 12 (2013), 657–660.
53. Minard-Colin, V., Xiu, Y., Poe, J.C., Horikawa, M., Magro, C.M., Hamaguchi, Y., Haas, K.M., Tedder, T.F., Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112 (2008), 1205–1213.
54. Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N., Bousso, P., The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123 (2013), 5098–5103.
55. Nelson, A.L., Dhimolea, E., Reichert, J.M., Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9 (2010), 767–774.
56. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
57. Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
58. Nimmerjahn, F., Bruhns, P., Horiuchi, K., Ravetch, J.V., FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005), 41–51.
59. Otten, M.A., van der Bij, G.J., Verbeek, S.J., Nimmerjahn, F., Ravetch, J.V., Beelen, R.H., van de Winkel, J.G., van Egmond, M., Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181 (2008), 6829–6836.
60. Pallasch, C.P., Leskov, I., Braun, C.J., Vorholt, D., Drake, A., Soto-Feliciano, Y.M., Bent, E.H., Schwamb, J., Iliopoulou, B., Kutsch, N., et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156 (2014), 590–602.
61. Pincetic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebiger, B.M., Ravetch, J.V., Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
62. Setiady, Y.Y., Coccia, J.A., Park, P.U., In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur. J. Immunol. 40 (2010), 780–786.
63. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
64. Takai, T., Li, M., Sylvestre, D., Clynes, R., Ravetch, J.V., FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994), 519–529.
65. Takai, T., Ono, M., Hikida, M., Ohmori, H., Ravetch, J.V., Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379 (1996), 346–349.
66. Teixeira, H.C., Kaufmann, S.H., Role of NK1.1+ cells in experimental listeriosis. NK1+ cells are early IFN-gamma producers but impair resistance to Listeria monocytogenes infection. J. Immunol. 152 (1994), 1873–1882.
67. Turaj, A.H., Hussain, K., Cox, K.L., Rose-Zerilli, M.J.J., Testa, J., Dahal, L.N., Chan, H.T.C., James, S., Field, V.L., Carter, M.J., et al. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell 32 (2017), 777–791.e6.
68. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199 (2004), 1659–1669.
69. Velmurugan, R., Challa, D.K., Ram, S., Ober, R.J., Ward, E.S., Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Mol. Cancer Ther. 15 (2016), 1879–1889.
70. Verschoor, A., Karsten, C.M., Broadley, S.P., Laumonnier, Y., Köhl, J., Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments. Immunol. Rev. 274 (2016), 112–126.
71. Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., Ugolini, S., Innate or adaptive immunity? The example of natural killer cells. Science 331 (2011), 44–49.
72. Wessels, M.R., Butko, P., Ma, M., Warren, H.B., Lage, A.L., Carroll, M.C., Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92 (1995), 11490–11494.
73. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109 (2012), 6662–6667.
74. Yazawa, N., Hamaguchi, Y., Poe, J.C., Tedder, T.F., Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA 102 (2005), 15178–15183.